PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPWednesday 23rd October 2013, Holiday Inn Regents Park, London, UK

HTA UncoveredWorkshop Leaders:

Janice Haigh, Practice Leader, Market Access, Europe, Quintiles & Anke van Engen, Director Consulting, Quintiles

8.30am - 12.30pm

2013Holiday Inn Regents Park | LONDON, UK

Pharmaceutical Pricing& Reimbursement

21st & 22ndOCTOBER

• Patrick Mollon, Director Global HE&OR Critical Care,Novartis

• Anne-Toni Rodgers, Global Pricing and Market Access,AstraZeneca

• Peter Hertzman, Director, Bristol Myers Squibb

• Martin Brown, Director, Novartis

• Franz Pichler, Director, Global Public Policy, Eli Lilly & Co

• Sarah Pitiluck, Senior Director, Global Pricing &Reimbursement, Alexion Pharma

• Janice Haigh, Director Market Access, Quintiles

• Leslie Galloway, Chairman, Ethical Medicines IndustryGroup

• Kirsten Bröckers, Senior Legal Advisor, Celgene

CONFERENCE SPEAKERS INCLUDEWHY ATTEND THIS EVENT

• Understand how value based pricing will affectthe U.Ks pricing market and what to expect

• Discuss key market access strategies with arange of case studies including those currentlybeing developed successfully with orphan drugs

• Evaluate current strategies with the new NICEnetwork reforms

• See the establishment of the pan-European HTAnetwork and its current effects

• Develop future cross sector market accessstrategies

SMi Presents their 19th annual

www.pharmaceuticalpricing.co.ukBOOK BY 28TH JUNE AND SAVE £300 I BOOK BY 19TH JULY AND SAVE £100

Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

BOOK B

Y

JUNE 2

8TH

AND SAVE £

300

BOOK B

Y JULY

19t

h

AND SAVE £

100 “2012 was a great demonstration of current events,

2013 is set for more of the same.”

Pharmaceutical Pricing & Reimbursement 2013Day One 21st October 2013

Register online at www.pharmaceuticalpricing.co.uk• Alternatively f

www.pharmaceu

Supported by

8.30 Registration & Coffee

9.00 Chairman's Opening RemarksDonald Macarthur, Global Pharmaceutical Business Analyst,

JustPharmaReports

VALUE BASED PRICING & FUTURE EFFECTS

9.10 Getting ready for value-based pricing: What can we do to prepare?• Planning for value based pricing in product development

• Considering a broader definition of value

• Developing an understanding of the new pricing process

Martin Brown, Head of Health Economics and Outcomes

Research, Novartis

9.50 Value Based Pricing• Implications for PPRS

• What is outside the negotiations?

• How will value be measured?

Leslie Galloway, Chairman, Ethical Medicines Industry Group

10.30 Morning Coffee

HTA & VALUE DELIVERY

11.00 Establishment of the permanent pan-European HTA network: implications for HTA and coverage decision making• Timeline and process to the establishment of the network

• The role of EUnetHTA in terms of operational implementing

• Key activities proposed for the network and implications of

these activities for pharma

Franz Pichler, Director, Global Public Policy, Eli Lilly & Co

11.40 The challenge of value delivery• How do global value messages translate in the local

environment?

• What types of value messages best support local

negotiations?

• How do we make sure that the reimbursement price

agreed at national level becomes the realised price at

local level?

Janice Haigh, Practice Leader, Market Access, Europe,

Quintiles

12.20 Networking Lunch

1.50 Integration of Health-Economics and Market Access in the development of innovative drugs• Value-Based Development: need and opportunities todemonstrate value

• Health-Economic strategies to anticipate Market Accessneeds

• Methods and Tools supporting value evidence generationPatrick Mollon, Director Global HE&OR Critical Care, Novartis

2.30 New Evidence on the Effectiveness Gap; How Pharma can deliver • The current problem: case studies in COPD and cancer• International comparisons of the effectiveness gap—France,UK,Germany and Finland

• Partnership with pharma and health services to delivertherapeutic results

Nick Basanquet, Professor of Health Policy, Imperial CollegeLondon

3.10 Afternoon Tea

3.40 No-one benefits from flying with empty planes: What options do we have to improve access in oncology? Experiences from Scandinavia• Patients are benefiting from many new and excitinginnovative oncology products. However, the discrepanciesbetween providers’ and payers’ expectations have still tobe resolved.

• There are various contractual options tested out in reality inorder to resolve the discrepancies. What are the pros andcons with these options

• Examples of the above from the Scandinavian marketsPeter Hertzman, Nordic Market Access Director, Bristol Myers Squibb

4.20 Implications of requiring traditional health economic assessments when evaluating ultra-orphan drugs • Traditional cost-effectiveness analyses are not anappropriate method to evaluate ultra-orphan drugs andcan have a negative impact on patient access totreatments

• Countries that require traditional economic analysesinappropriately disadvantage patients with ultra-rarediseases

• Instead, review agencies should look at a combination ofother factors when evaluating such drugs

Sarah Pitluck, Senior Director, Global Pricing &Reimbursement, Alexion Pharmaceuticals Inc

5.00 Chairman's Closing Remarks and Close of Day One

SPONSORSHIP OPPORTUNITIESOur pharmaceutical events are research-based and content-driven with regular contact with major industry personnel and cover a

wide range of industry sectors. For more information, please contact Alia Malick on +44 (0) 207 827 6168 or email amalick@smi-online.co.uk

fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

uticalpricing.co.uk

8.30 Registration & Coffee

9.00 Chairman's Opening RemarksDonald Macathur, Global Pharmaceutical Business Analyst,JustPharmaReports

U.K. MARKET ACCESS & NICE REFORMS

9.10 The new NICE and its global network • A new Leadership … a New NICE?• A UK Government Export - understand how NICEproactively shapes the Pricing & Reimbursementenvironment internationally

• Plan your global responseAnne-Toni Rodgers, Global Payer Lead, AstraZeneca

9.50 UK Market Access-post-change challenges• Specialised commissioning• Health informatics• Joint working• Case studyRichard Lomas, National Commissioning Manager MS,Genzyme

10.30 Morning Coffee

11.00 Key learnings of 2 years of AMNOG• Pricing and additional benefit• Do innovative drugs still have a chance?• Roadblocks moving forward• Case studyBertram Häussler, Director, IGES Institut

11.40 Healthcare reforms in Europe — How are they effecting P&R• A revisited welfare state: between cost containment andequal access

• Forward enlarged private HC expenditure• Devoluting locally HC and pharma management• Narrow price corridors, parallel trade and economicdifferentials among EU Countries

• New models and schemes of P&R to face both costcontainment and equal access

• Different formularies management nationally and locallyFabrizio Gianfrate, Professor of Health Economics, Universityof Ferrara

12.20 Networking Lunch

HEALTHCARE REFORMS & EU TRANSPARENCY

1.50 Pricing of pharmaceuticals in a resource constrained

environment

• Healthcare policies in a period of recession

• Policies relating to pharmaceuticals during recessionary

periods

• New initiatives in pharmaceutical pricing

• The role of HTA

Ceri Phillips, Professor of Health Economics and Head of the

Institute for Health Research, Swansea University

2.30 Session reserved for Celgene

Kirsten Bröckers, Senior Legal Advisor, Celgene

3.10 Afternoon Tea

3.40 Japan: The Land that Cost Containment Forgot

• Pricing environment in Japan vs leading western countries

• Price comparisons

• Market entry strategies

• Prospects for change

Donald Macarthur, Global Pharmaceutical Business Analyst,

JustPharmaReports

4.20 Reform of the EU transparency directive

• The push for reform – issues not covered in the 1989

Directive

• The content and status of the reform proposal

• Next steps – when the changes will take effect in practice

James Killick, Partner, White & Case L L P

5.00 Chairman's Closing Remarks and Close of Day Two

Supported by

Want to know how you can get involved? Interested in promoting your pharmaceutical services to this market? Contact Margaret Mugema,

SMi Marketing on +44 (0)20 7827 6072 or email mmugema@smi-online.co.uk

Day Two Tuesday 22nd October 2013

Overview of workshop

Understand the HTA World globally. Quintiles tracks100 agencies around the world to monitor andunderstand their decision making processes. Themain part of the workshop will provide a factualunderstanding of the HTA map – who are the keyagencies, from what perspective is their evaluation,what types of evidence do they require, whattypically drives HTA success or failure?

The final part of the workshop will reveal somesecrets about the main HTA bodies – what are therules which are not published, which agencies arethe most influential, what you can’t learn frominterviews or ad-boards.

Note: attendees from pharma companies only.

Programme:

8.30 Registration & Coffee

9.00 Understanding the HTA map• Key agencies

• Types of assessment and evaluation

• Differences and similarities

11.00 Break for Coffee

11.30 HTA uncovered• Drivers of success and failure

• What they dont print in the rules

12.00 Q&A

12.30 Close of workshop

About the workshop hosts:

Janice Haigh Practice Leader, Market Access,QuintilesJanice joined Quintiles Consulting in January 2012as Practice Leader for Market Access in Europe.From 2006 to December 2011, Janice was theSenior Director Pricing and Market Access forAstellas Pharma, Europe and was responsible fordevelopment and implementation of pricing andmarket access strategy for new and in marketproducts, working closely with brand teams andaffiliates price management, analysing the effectof price changes on other markets. Janice alsodesigned, implemented and managed Astellas’ssupply chain integrity program which ensured thematching of supply and demand of products inEurope. Before joining Astellas in 2006, Janiceworked in consultancy for 20 years, includingalmost 10 years at IMS Health/Cambridge PharmaConsultancy where she was responsible for leadingprojects involving pricing, parallel trade, healtheconomics and health policy. Clients includedEuropean and global pharmaceutical companiesbut also trade associations and governmentbodies such as the European Commission.

HTA Uncovered

HALF-DAY POST-CONFERENCE AM WORKSHOP23rd October 2013,

Holiday Inn Regents Park, London8.30am - 12.30pm

In association with

Janice Haigh, Practice Leader, Market Access, Europe,Quintiles &

Anke van Engen, Director Consulting, Quintiles

SMi PHARMACEUTICALSFORWARD PLANNER 2013

JUNE

RNAi & Nanotechnology5 - 6 June 2013, London

Biobanking24 - 25 June 2013, London

JULY

Pharmacovigilance1 - 2 July 2013, London

Cell Culture3 - 4 July 2013, London

SEPTEMBER

Cancer Vaccines18 - 19 September 2013, London

OCTOBER

Biosimilars & Biobetters1 - 2 October 2013, London

Diabetes1 - 2 October 2013, London

Orphan Drugs14 - 15 October 2013, London

COPD: Novel Therapeutics andManagement Strategies

16 - 17 October 2013, London

European Pharmaceutical Pricing & Reimbursement

21 - 22 October 2013, London

Point of Care Diagnostics - Market Opportunities and

Technology Trents23 - 24 October 2013, London

NOVEMBER

Cell Based Assays18 - 19 November 2013, London

Clinical Trials in CNS18 - 19 November 2013, London

DECEMBER

Cold Chain Distribution3 - 4 December 2013, London

PHARMACEUTICAL PRICING & REIMBURSEMENTConference: 21 & 22 October | Holiday Inn Regents Park | LONDON, UK Workshops: 23rd October 2013, London

4 WAYS TO REGISTER

FAX your booking form to +44 (0) 870 9090 712

PHONE on +44 (0) 870 9090 711

www.pharmaceuticalpricing.co.uk

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk

□ Book by 28th June to receive £300 off the conference price□ Book by 19th July to receive £100 off the conference price

EARLY BIRDDISCOUNT

Payment must be made to SMi Group Ltd, and received before the event, by one ofthe following methods quoting reference P-085 and the delegate’s name. Bookingsmade within 7 days of the event require payment on booking, methods of paymentare below. Please indicate method of payment:□ UK BACS Sort Code 300009, Account 00936418□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU

Swift (BIC): LOYDGB21013, Account 00936418IBAN GB48 LOYD 3000 0900 9364 18

□ Cheque We can only accept Sterling cheques drawn on a UK bank.□ Credit Card □ Visa □ MasterCard □ American Express

All credit card payments will be subject to standard credit card charges.

Card No: □□□□ □□□□ □□□□ □□□□Valid From □□/□□ Expiry Date □□/□□CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card

Cardholder’s Name:

Signature: Date:I agree to be bound by SMi's Terms and Conditions of Booking.

Card Billing Address (If different from above):

CONFERENCE PRICES

DOCUMENTATION (Shipped 10-14 days after the

I would like to attend: (Please tick as appropriate) Fee Total

□ Conference & 2 Workshops £2697.00 + VAT £3236.40

□ Conference & 1 Workshop £2098.00 + VAT £2517.60

□ Conference only £1499.00 + VAT £1798.80

□ 1 Workshop only £599.00 + VAT £718.80

□ 2 Workshops only £1198.00 + VAT £1437.60

Workshop A □ Workshop B □

PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional

literature to all conference attendees £999.00 + VAT £1198.80

GROUP DISCOUNTS AVAILABLE

The Conference fee includes refreshments, lunch, conference papers and CD ROM containing all of the presentations.

I cannot attend but would like to purchase access to the following DocumentPortal/paper copy documentation: Price Total□ Access to the conference documentation

on the Document Portal £499.00 + VAT £598.80□ The Conference Presentations - paper copy £499.00 - £499.00

(or only £300 if ordered with the Document Portal)

VATVAT at 20% is charged on the attendance fees for all delegates. VAT is also chargedon CD ROMs and Literature Distribution for all UK customers and for those EUcustomers not supplying a registration number for their own country here:_______________________

PAYMENT

POST your booking form to: Events Team, SMi Group Ltd, 2nd FloorSouth, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS

Payment: If payment is not made at the time of booking, then an invoice will be issued and mustbe paid immediately and prior to the start of the event. If payment has not been received thencredit card details will be requested and payment taken before entry to the event. Bookings within7 days of event require payment on booking. Access to the Document Portal will not be given untilpayment has been received.

Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, anotherdelegate to take your place at any time prior to the start of the event. Two or more delegates maynot ‘share’ a place at an event. Please make separate bookings for each delegate.

Cancellation: If you wish to cancel your attendance at an event and you are unable to send asubstitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providingthat cancellation is made in writing and received at least 28 days prior to the start of the event.Regretfully cancellation after this time cannot be accepted. We will however provide theconferences documentation via the Document Portal to any delegate who has paid but is unableto attend for any reason. Due to the interactive nature of the Briefings we are not normally able toprovide documentation in these circumstances. We cannot accept cancellations of ordersplaced for Documentation or the Document Portal as these are reproduced specifically to order.If we have to cancel the event for any reason, then we will make a full refund immediately, butdisclaim any further liability.

Alterations: It may become necessary for us to make alterations to the content, speakers, timing,venue or date of the event compared to the advertised programme.

Data Protection: The SMi Group gathers personal data in accordance with the UK Data ProtectionAct 1998 and we may use this to contact you by telephone, fax, post or email to tell you aboutother products and services. Unless you tick here □ we may also share your data with third partiesoffering complementary products or services. If you have any queries or want to update any ofthe data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed aboveyour address on the attached letter.

Unique Reference Number

Our Reference P-085

Terms and Conditions of Booking

DELEGATE DETAILSPlease complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename:

Surname:

Job Title:

Department/Division:

Company/Organisation:

Email:

Address:

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

Mobile:

Switchboard:

Signature: Date:I agree to be bound by SMi's Terms and Conditions of Booking.

ACCOUNTS DEPT

Title: Forename:

Surname:

Email:

Address (if different from above):

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

VENUE Holiday Inn Regents Park, Carburton Street, London W1W 5EE

□ Please contact me to book my hotelAlternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712